Scott Platshon
Executive VP & Chief Business OfficerMr. Scott Platshon, BSc., is Executive VP and Chief Business Officer of Zymeworks Inc. from April 9, 2026. He serves as a Director of Theravance Biopharma, Inc. since September 23, 2026. He was Acting Chief Investment Officer of Zymeworks Inc. from November 2025 to April 9, 2026. He was Independent Director of Zymeworks Inc. from February 22, 2024 to November 2025. He is Director of Kumquat Biosciences Inc. He is Chief Operating Officer of Panacea Acquisition Corp. II from January 2021. He was Partner of EcoR1 Capital, LLC from 2021 to April 2026. He was Principal of EcoR1 Capital, LLC until 2021. He was employed at EcoR1 Capital, LLC from October 2015 to April 2026. He was Independent Director of Silverback Therapeutics, Inc. from September 2020 to December 03, 2020. He was employed at Silverback Therapeutics, Inc. until December 03, 2020. He was Director of Ajax Therapeutics, Inc. He was Chief Operating Officer of Panacea Acquisition Corp. from April 2020. He has B.S. in Bio Engineering from Stanford University.
Positions
- Company NameZymeworks Inc.Stock CodeZYMEPositionExecutive VP & Chief Business OfficerColleagues
- KHKenneth H. GalbraithChairman of the Board, CEO & President
- PAPaul A. MooreChief Scientific Officer
- KSKristin StaffordExecutive VP & CFO
- MHMark HollywoodExecutive VP & COO
- SMSusan M. MahonyLead Independent Director
- CECarlos E. CampoyIndependent Director
- GAGregory Austin CiongoliIndependent Director
- KMKelvin M. NeuIndependent Director
